About us

Laurent Pharma is a late stage clinical biotech company focusing on developing treatments for complex conditions caused by an unbalanced immune-inflammatory response.


Targeting cell membrane lipid composition and fluidity as a new paradigm for regulating host defense and the inflammation process.


Laurent Pharma has completed two Phase 2 clinical studies with LAU-7b, a first-in-class proresolving drug candidate, in cystic fibrosis and COVID-19.

LAU-7b is an oral drug candidate that showed potential to regulate membrane lipids and exert antiviral, inflammation-controlling, and antifibrotic properties.    

News & Events

Laurent Pharmaceuticals presents data with LAU-7b in Idiopathic Pulmonary Fibrosis at the  2024 ATS International Conference,  May 17-22, San Diego, CA, USA
Laurent Pharma to participate to BIO International Convention, June 3-6, 2024, San Diego, CA, USA